Table of Contents

State/Territory Name: NE

State Plan Amendment (SPA) #: 16-0013 Pharmacy

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

November 17, 2016

Calder Lynch, Medicaid Director Department of Health and Human Services Division of Medicaid and Long-Term Care 301 Centennial Mall South, 5th Floor P.O. Box 95026 Lincoln, NE 68509-0250

Dear Mr. Lynch:

We have reviewed the Nebraska State Plan Amendment (SPA) 16-0013 received in the Kansas City Regional Office on October 5, 2016. This amendment updates the terms upon which the state intends to collect supplemental rebates from drug manufacturers with continued participation in The Optimal PDL \$olution (TOP\$ SM), a multi-state pooling supplemental rebate agreement (SRA). The TOP\$ SM SRA includes the terms upon which the state will collect supplemental rebates from drug manufacturers on those drugs dispensed to Medicaid Managed Care Organization (MCO) enrollees. Based upon the information provided, we are pleased to inform you that SPA 16-0013 is approved with an effective date of January 1, 2017.

A copy of the CMS-179 form, as well as the pages approved for incorporation into the Nebraska state plan, will be forwarded by the Kansas City Regional Office. If you have any questions regarding this amendment, please contact Renee Hilliard at (410) 786-2991.

Sincerely,

John M. Coster, Ph.D., R.Ph. Director, Division of Pharmacy CMS, CMCS/DEHPG

cc: James G. Scott, ARA, Kansas City Regional Office

HEALTH CARE FINANCING ADMINISTRATION		APPROVED NO. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER: 16-00132. STATE Neb	raska
FOR: HEALTH CARE FINANCING ADMINISTRATION	HEALTH CARE FINANCING ADMINISTRATION 3. PROGRAM IDENTIFICATION: TITLE XIX SOCIAL SECURITY ACT (MEDICAID)	
TO: REGIONAL ADMINISTRATOR HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE January 1, 2017	
5. TYPE OF PLAN MATERIAL (Check One):	CONSIDERED AS NEW PLAN	DMENT
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMEN		DIVIDITI
6. FEDERAL STATUTE/REGULATION CITATION:	7. FEDERAL BUDGET IMPACT:a. FFY 2017b. FFY 2018	
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPERSEDED PLAN OR ATTACHMENT (If Applicable):	SECTION
Attachment 3.1-A, Item 12a, Page 4	Attachment 3.1-A. Item 12a, Page 4	
Limitations-Prescribed Drugs 11. GOVERNOR'S REVIEW (Check One): GOVERNOR'S OFFICE REPORTED NO COMMENT	OTHER, AS SPECIFIED: Governor has waived review	
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	Obverhor has warved review	
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL		
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL 12. SIGNATURE OF SPATE AGENCY OFFICIAL: 14. TYPED NAME: Catder Lynch 14. TITLE: Director, Division of Medicaid and Long-Term Care 15. DATE SUBMITTED: 	16. RETURN TO: Nancy Keller Division of Medicaid & Long-Term Care Nebraska Department of Health & Human Services 301 Centennial Mall South Lincoln, NE 68509	
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL 12. SIGNATURE OF SWATE AGENCY OFFICIAL: 14. TITLE: Director, Division of Medicaid and Long-Term Care 15. DATE SUBMITTED: October 5, 2016 	 16. RETURN TO: Nancy Keller Division of Medicaid & Long-Term Care Nebraska Department of Health & Human Services 301 Centennial Mall South Lincoln, NE 68509 	
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL 12. SIGNATURE OF SWATE AGENCY OFFICIAL: 14. TYPED NAME: Catder Lynch 14. TITLE: Director, Division of Medicaid and Long-Term Care 15. DATE SUBMITTED: October 5, 2016 FOR REGIONAL OF 17. DATE RECEIVED: October 5, 2016 	 16. RETURN TO: Nancy Keller Division of Medicaid & Long-Term Care Nebraska Department of Health & Human Services 301 Centennial Mall South Lincoln, NE 68509 FICE USE ONLY 18. DATE APPROVED: November 17, 2016 	
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL 12. SIGNATURE OF SWATE AGENCY OFFICIAL: 14. TITLE: Director, Division of Medicaid and Long-Term Care 15. DATE SUBMITTED: October 5, 2016 FOR REGIONAL OF 17. DATE RECEIVED: October 5, 2016 	 16. RETURN TO: Nancy Keller Division of Medicaid & Long-Term Care Nebraska Department of Health & Human Services 301 Centennial Mall South Lincoln, NE 68509 FICE USE ONLY 18. DATE APPROVED: November 17, 2016 E COPY ATTACHED 	
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL 12. SIGNATURE OF SWATE AGENCY OFFICIAL: 14. TYPED NAME: Catder Lynch 14. TITLE: Director, Division of Medicaid and Long-Term Care 15. DATE SUBMITTED: October 5, 2016 FOR REGIONAL OF 17. DATE RECEIVED: October 5, 2016 	 16. RETURN TO: Nancy Keller Division of Medicaid & Long-Term Care Nebraska Department of Health & Human Services 301 Centennial Mall South Lincoln, NE 68509 FICE USE ONLY 18. DATE APPROVED: November 17, 2016 	

ATTACHMENT 3.1-A Item 12a, Page 4 Applies to both Categorically and Medically Needy

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT State <u>Nebraska</u> LIMITATIONS – PRESCRIBED DRUGS

Supplemental Rebate Program:

The state is in compliance with Section 1927 of the Social Security Act. Based on the requirements of Section 1927 of the act, the state has the following policies for the supplemental rebate program for Medicaid recipients:

- a) All covered drugs of federal participating manufacturers remain available to the Medicaid program but may require prior authorization.
- b) CMS has authorized the State of Nebraska to enter into the TOP\$sm, *The Optimal PDL \$olution* ("TOP\$sm") multi state pooling agreement to collect supplemental rebates through the TOP\$sm program. The Supplemental Drug Rebate Agreement was submitted to CMS on October 5, 2016 and has been authorized by CMS, effective January 1, 2017.
- c) Any contracts not authorized by CMS will be submitted to CMS for authorization.
- d) Any changes to the contracts for the TOP\$SM program will be submitted to CMS for approval.
- e) All drugs covered by this program irrespective of a supplemental agreement, will comply with the provisions of the National Drug Rebate Agreement.
- f) The State will negotiate supplemental rebates in addition to federal rebates provided for in Title XIX.
- g) Supplemental rebates received by Nebraska in excess of those required under the National Drug Rebate Agreement will be shared with the federal government on the same percentage basis as applied under the National Drug Rebate Agreement.
- h) Supplemental rebate agreements would apply to the drug benefit, both fee-forservice and those paid by contracted managed care organizations (MCOs).
- i) The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification, in accordance with Section 1927(b)(3)(D).
- j) Rebates paid under the CMS-authorized TOP\$sm for the Nebraska Medicaid population do not affect AMP or best price under the Medicaid program.
- k) The CMS-authorized TOP\$sm Agreement for the Nebraska Medicaid population only covers supplemental rebates for Medicaid programs. It does not cover non-Medicaid programs.
- I) Pharmaceutical manufacturers are allowed to audit utilization rates.

TN No. <u>NE-16-0013</u>		
Supersedes	Approval Date November 17, 2016	Effective Date January 1, 2017
TN No. <u>NE 13-25</u>		